Pregnancy: newer antidepressants linked to persistent pulmonary hypertension in newborns


The women who are taking antidepressants known as SSRI ( selective serotonin reuptake inhibitors ), and who are pregnant or intend to become pregnant, should discuss the situation with their doctor due to potential risks to the baby.

The patients should not stop taking SSRI medication without first consulting their doctors, as they could experience serious side effects.

Generally, SSRI treatment should only be continued if the benefits to the individual patient are thought to outweigh the risks to the unborn child, while also considering the benefits and risks of switching to another treatment option or stopping treatment altogether.

SSRIs and other newer antidepressants prescribed for the treatment of depression include the following drugs: Wellbutrin ( Bupropion ), Celexa ( Citalopram ), Cipralex ( Escitalopram ), Prozac ( Fluoxetine ), Luvox ( Fluvoxamine ), Remeron ( Mirtazapine ), Paxil ( Paroxetine ), Zoloft ( Sertraline ) and Effexor ( Venlafaxine ), and Zyban ( Bupropion ) for smoking cessation.

A study published recently in the New England Journal of Medicine ( NEJM ) suggests that use of SSRIs during the second half of pregnancy may be associated with a condition called persistent pulmonary hypertension of the newborn.
Newborns with this rare but life-threatening condition do not receive enough oxygen in the blood and require intensive-care treatment to survive.
According to the study, babies born with this condition were six times more likely than healthy babies to have been exposed to SSRIs.

Numerous reports in Canada and abroad have already indicated that some children exposed to SSRIs and other newer antidepressants during pregnancy may develop serious complications at birth. An increase in the overall risk of major birth defects has also been associated with SSRI use.

Source: Health Canada, 2006


XagenaMedicine_2006


Altri articoli

Specialità ( Italian version )